J
Judith A. Hahn
Researcher at University of California, San Francisco
Publications - 207
Citations - 9289
Judith A. Hahn is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 46, co-authored 171 publications receiving 8517 citations. Previous affiliations of Judith A. Hahn include University of California, Berkeley & University of California.
Papers
More filters
Journal ArticleDOI
Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods
David Alland,Gary E. Kalkut,Andrew R. Moss,Ruth Mcadam,Judith A. Hahn,William Bosworth,Ernest Drucker,Barry R. Bloom +7 more
TL;DR: In the inner-city community the authors studied, recently transmitted tuberculosis accounts for approximately 40 percent of the incident cases and almost two thirds of drug-resistant cases.
Journal ArticleDOI
Hepatitis C Virus Seroconversion among Young Injection Drug Users: Relationships and Risks
Judith A. Hahn,Kimberly Page-Shafer,Paula J. Lum,Philippe Bourgois,Ellen Stein,Jennifer L. Evans,Michael P. Busch,Leslie H. Tobler,Bruce Phelps,Andrew R. Moss +9 more
TL;DR: Ubiquitous behaviors among young IDUs, such as the forming of injecting or sexual partnerships and consequent sharing of needles and drug preparation equipment, are risk factors for HCV.
Journal ArticleDOI
Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study).
Jennifer L. Evans,Judith A. Hahn,Kimberly Page-Shafer,Paula J. Lum,Ellen Stein,Peter J. Davidson,Andrew R. Moss +6 more
TL;DR: In logistic regression models for borrowing a used needle and sharing drug preparation equipment, increased risk in females was explained by having an injection partner who was also a sexual partner, and injecting risk was greater in the young female compared to male IDUs despite equivalent frequency of injecting.
Journal ArticleDOI
Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: Results in 90 patients
Jeanne M. LaBerge,Kenneth A. Somberg,John R. Lake,Roy L. Gordon,Robert K. Kerlan,Nancy L. Ascher,John P. Roberts,Margaret M. Simor,Catherine A. Doherty,Judith A. Hahn,Peter BachettiI,Ernest J. Ring +11 more
TL;DR: Although mid-term primary patency is limited in many patients by the development of a shunt stenosis or occlusion, shunt function can be maintained in most patients by careful surveillance and periodic percutaneous intervention.
Journal ArticleDOI
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
Norah A. Terrault,Shuan Zhou,Connie Combs,Judith A. Hahn,John R. Lake,John P. Roberts,Nancy L. Ascher,Teresa L. Wright +7 more
TL;DR: A fixed monthly dose of HBIg reduces the recurrence of HBs antigenemia, even in patients with indices of active viral replication pretransplantation, and the presence of residual virus in the majority of patients administered H BIg suggests that long‐term HBIG administration may be necessary.